Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment

Inclusion Criteria:

* Patients ≥ 18 years and ≤ 70 years of age, male or female
* Histologically/radiologically diagnosed advanced unresectable hepatocellular carcinoma
* Patients had received sorafenib as systemic therapy for advanced HCC with radiographic assessment of Stable Disease (SD) according to mRECIST criteria
* ECOG performance status of 0-2
* Child-Pugh score ≤ 7
* At least one measurable target lesion according to mRECIST and at least one lesion ≥ 10 mm; the lesions previously treated by radiotherapy or local regional therapy must have imaging evidence of disease progression to be considered as target lesions
* Life expectancy ≥ 3 months
* A) White blood cell count ≥ 3.0 × 10 \^ 9/L, absolute neutrophil count ≥ 3.0 × 10 \^ 9/L, platelet count ≥ 50 × 10 \^ 9/L, hemoglobin \> 100 g/L; B) INR ≤ 1.5 times the upper limit of normal, APTT ≤ 1.5 times the upper limit of normal or PTT ≤ 1.5 times the upper limit of normal; C) Total bilirubin ≤ 2.5 times the upper limit of normal; ALT and AST ≤ 5 times the upper limit of normal; serum creatinine ≤ 1.5 times the upper limit of normal
* Voluntarily participate in this study and sign the informed consent
* Female patients of childbearing age or male patients with sexual partners of childbearing age should take effective contraceptive measures throughout the treatment period and 6 months after treatment

Exclusion Criteria:

* Pregnant or lactating women
* Diffuse liver cancer or tumor not amenable to mRECIST criteria
* Prior treatment with oncolytic virus (e.g., T-VEC)
* Patients who are known to be allergic to the study drug or its active ingredients
* Sorafenib administration \< 14 days
* History of immunodeficiency or autoimmune disease, or chronic systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to enrollment
* Patients with any other unstable systemic disease or other malignancy that may reduce life expectancy
* Patients participate in another interventional clinical trial within 30 days